Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics Prime
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

cross-border merger of Bioalliance Pharma SA and Topotarget is legally effective as of July 22, 2014


Wednesday, 23 Jul 2014 02:00pm EDT 

Bioalliance Pharma SA:Says that cross-border merger between two companies is legally effective as of July 22, 2014 to create Onxeo, dedicated to orphan oncology diseases.